365Telugu.com online news,India,June 4th, 2025:Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715), along with its subsidiaries and associated companies (“Sun Pharma”), has announced the top-line results from its Phase 2 clinical trials evaluating SCD-044, an investigational oral S1P receptor 1 agonist, for the treatment of moderate to severe plaque psoriasis and atopic dermatitis.
In the Phase 2 study for moderate to severe plaque psoriasis, SCD-044 did not meet the primary endpoint of achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI75) at Week 16. The randomized, double-blind, placebo-controlled trial enrolled 263 participants.
Read This also…Google Maps Speedometer: Avoid Traffic Fines Easily..
Read This also…18Years Dream is Fulfilled..
Similarly, in the Phase 2 trial for moderate to severe atopic dermatitis, SCD-044 failed to meet the primary endpoint of 75% improvement in the Eczema Area and Severity Index (EASI75) at Week 16. This study included 250 participants and evaluated three different dosage levels of SCD-044 compared to placebo.
Dr. Marek Honczarenko, Senior Vice President and Head of Global Specialty Development at Sun Pharma, stated, “While the results are disappointing, we are grateful to all the patients, healthcare providers, and clinical staff who participated in these important studies.”
Read This also…RCB vs PBKS Face Off in IPL 2025 Final Tonight..
ఇది కూడా చదవండి…హ్యుందాయ్ కొత్త ప్రచారం: పంకజ్ త్రిపాఠి తో ‘లిజన్ టు యువర్ దిల్ ఆర్ ది డీల్స్’..
Importantly, no major safety or tolerability issues were observed in either trial. However, based on the findings, Sun Pharma has decided to discontinue further clinical development of SCD-044. The company and its R&D partner, Sun Pharma Advanced Research Company Ltd., will now review future options for the asset.